NYSE · Drug Manufacturers - Specialty & Generic · USD
Takeda Pharmaceutical Company Limited (TAK) Stock Analysis
Takeda Pharmaceutical Company Limited (TAK) is a Drug Manufacturers - Specialty & Generic stock listed on NYSE and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
TAK Key Statistics
As of Oct 21, 2026Trading
- Open
- $19.90
- Previous Close
- $20.08
- Day's Range
- 19.90–20.03
- 52-Week Range
- 12.99–20.13
- Volume
- 1.67M
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.10
Valuation
- Market Cap
- $63.67B
- P/E Ratio
- unprofitable
- Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
- 37.60
- PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
- 0.45
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.34
Financials (FY)
- Revenue (FY)
- $4.51T−1.66%
- Net Income (FY)
- −$152.39B−241.20%
- Profit marginThe share of revenue left as profit after all costs and taxes.
- −3.54%
- Shares Outstanding
- 3.19B
- 1-Year Return
- +41.25%
Dividend and dates
- Dividend
- $0.62+3.07%
- Ex-Dividend Date
- March 31, 2026
- Earnings Date
- October 29, 2026
- Avg Volume
- 2.89M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, TAK closed at $19.93, +41.25% over 1 year.
Takeda Pharmaceutical Company Limited (TAK) has a market capitalization of $63.67B.
In fiscal 2025, TAK reported revenue of $4.51T.
TAK Stock Return by Calendar Year
Takeda Pharmaceutical Company Limited (TAK) 10-year return: what $10,000 became
- 1 year
- $10,000 $14,125
- +41.25%
- 5 years
- $10,000 $15,185
- +51.85%
- 10 years
- $10,000 $9,325
- −6.75%
If you had invested $10,000 in Takeda Pharmaceutical Company Limited (TAK) 10 years ago, at the close on October 21, 2016, it would have been worth $9,325 at the close on October 21, 2026: −6.75% in total, −0.70% a year, with dividends reinvested. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +27.84% |
| 2025 | +20.46% |
| 2024 | −3.12% |
| 2023 | −8.53% |
| 2022 | +14.45% |
| 2021 | −25.11% |
| 2020 | −7.75% |
| 2019 | +17.30% |
| 2018 | −40.88% |
| 2017 | +36.91% |
| 2016 (partial year) | −10.78% |
As of October 21, 2026.
TAK Revenue and Earnings by Fiscal Year
FY ends March| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $4.51T | −$152.39B | −3.4% |
| 2024 | $4.58T | $107.93B | 2.4% |
| 2023 | $4.26T | $144.07B | 3.4% |
| 2022 | $4.03T | $317.02B | 7.9% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $4.51T | $2.93T | $464.45B | −$152.39B | −3.4% |
| 2024 | $4.58T | $3.00T | $466.37B | $107.93B | 2.4% |
| 2023 | $4.26T | $2.84T | $309.90B | $144.07B | 3.4% |
| 2022 | $4.03T | $2.78T | $587.81B | $317.02B | 7.9% |
Annual figures as reported, in the company's reporting currency. As of March 31, 2026.
TAK Dividend History
Dividends per share, 2025 · 1 payments
| Year | Dividends per share | Payments | Change |
|---|---|---|---|
| 2025 | $0.34 | 1 | −45.1% |
| 2024 | $0.62 | 2 | — |
Most recent payment: $0.34 per share, ex-dividend March 31, 2025. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.
TAK Valuation vs Drug Manufacturers - Specialty & Generic Median
Median of 97 stocks| Metric | TAK | Drug Manufacturers - Specialty & Generic median | vs median |
|---|---|---|---|
| P/S ratio | 0.01 | 2.10 | 0.0x the median |
| Profit margin | −3.54% | −8.14% | 4.6 pts above |
Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
Disease Clearance Data Might Change The Case For Investing In Takeda (TSE:4502)
YahooTakeda Announces New Data From VERDICT Showing That Treating Adults With Intravenous ENTYVIO To Achieve Corticosteroid-Free Disease Clearance Resulted In Significantly Longer Time To First Ulcerative Colitis-Related Complication, Reducing UC Complication Risk By Nearly 70%
BenzingaReported Earlier, Takeda Launches ORZEYFUL In Japan And China As First-In-Class Orexin Agonist For Narcolepsy Type 1, With US Launch Set For Next Month After DEA Scheduling
BenzingaTakeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
YahooTakeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026
YahooTakeda Remains A Buy, Boosted By Recent Narcolepsy Drug Approval And Robust Pipeline
SeekingAlpha
All 20 articles ↓Show fewer ↑
Takeda (TSE:4502) Stock Looks Below Fair Value Even After A 120% Run
YahooCorus International Receives $6.4 Million Grant From Takeda to Reduce Climate-Related Health Risks in Nepal
YahooWill Zasocitinib’s Phase 3 Outperformance Reshape Takeda Pharmaceutical's (TSE:4502) Immunology-Driven Pipeline Narrative
YahooTakeda Pharmaceutical (TSE:4502) Could Be 13% Undervalued On Strong Phase 3 Psoriasis Data
YahooTakeda Reports New Psoriasis Treatment Outperformed Competitor in Phase 3 Trial
YahooTakeda Presents Phase 3 Data Showing Once-Daily Oral Zasocitinib Delivers Higher PASI 100 At 36.5% Vs 13.9% And PASI 90 At 62.5% Vs 34.0% Than Deucravacitinib At Week 16; Under FDA, EMA Review For Plaque Psoriasis
BenzingaGinkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
YahooKeros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After Dosing Of First Patient In The ELRiSE MF Clinical Trial
BenzingaInnovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC
YahooTakeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026
YahooTakeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems
YahooTakeda Pharmaceutical (TAK) Gets Priority Review. Can Zasocitinib Win in Psoriasis?
YahooFull Transcript: Takeda Pharmaceutical Co Q1 2026 Earnings Call
BenzingaTakeda Pharmaceutical Company Limited (TAK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
SeekingAlpha
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Drug Manufacturers - Specialty & Generic Stocks
Teva Pharmaceutical Industries Limited
$47.37B
HLNHaleon plc
$44.06B
ZTSZoetis Inc.
$32.90B
UTHRUnited Therapeutics Corporation
$24.17B
VTRSViatris Inc.
$21.19B
NBIXNeurocrine Biosciences, Inc.
$14.36B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B